The formation of a diversified biopharmaceutical company through the agreement with Ceapro is likely to be viewed positively by investors, as it could lead to new growth avenues and synergies. However, the impact is somewhat tempered by the fact that the transaction is expected to close in the future (Q1 2024), which adds a degree of uncertainty.

Ceapro's agreement with Aeterna Zentaris is expected to open up new opportunities for the company in terms of expansion and collaboration within the biopharmaceutical industry. Similar to AEZS, the positive impact is somewhat moderated by the future closing date of the transaction.